HomeTrialNCT06724900
🔬NCT06724900Phase 1Phase 2ACTIVE NOT RECRUITING

A Study Assessing KB304 for the Treatment of Wrinkles in Women

Study Summary

The aim of this study is to investigate the safety and efficacy of KB304, an investigational gene therapy to correct moderate to severe wrinkles in the décolleté region (V-shaped chest area). KB304 is an investigational gene therapy that delivers functional, full-length human collagen (COL3) and elastin (tropoelastin) to the skin through small injections using the Sponsor's genetically engineered Herpes Simplex Virus (HSV-1) vector. The study is a randomized double-blind study and participants will receive either KB304 (active group) or placebo (inactive group).

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment19 participants
Primary Completion
Lead SponsorKrystal Biotech, Inc.
Data Retrieved2026-04-11 04:19:09.549410+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.